Corporate Profile for Atlantic Pharmaceuticals, Inc., dated May 17, 1996.--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and information services See Information Systems. . These include Dow Jones Dow Jones the best known of several U.S. indexes of movements in price on Wall Street. [Am. Hist.: Payton, 202] See : Finance News/Retrieval, Bloomberg Financial Markets, Reuter Company Newsyear, Reuter Business Briefing, DataTimes, Nexis, Dialog, NewsNet, America OnLine See AOL. , CompuServe, Delphi, Individual's HeadsUp and First!, Desktop Data's NewsEdge, UMI UMI University Microfilms International UMI United States Minor Outlying Islands (ISO Country code) UMI University of Miami UMI Universal Management Infrastructure (IBM) Data Courier, NewsBank, Information Access Company, Prodigy, Comtex, and many others. -0- Published date: May 17, 1996 Company name: Atlantic Pharmaceuticals, Inc.
Address: 142 Cypress Point Road
Half Moon Bay, CA 94019
Telephone No.: 415/726-1327 Chief Executive Officer: Jon D. Lindjord Chief Financial Officer: Shimshon Mizrachi Investor Relations Contact: Peggy Schalk Business number: 415/726-1327 e-mail address: peggy@atlan.com Public Relations Contact: Tony Russo, Noonan/Russo, Inc. Business number: 212/696-4455 e-mail address: tony@noonanrusso.com URL Address: http://www.atlan.com Trading symbol: ATLC; ATLCU; ATLCW Industry: Biopharmaceuticals -0- Company description: Atlantic Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development of a number of diverse pharmaceutical and biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. products and technologies for use in cataract removal and also for the treatment of cancer, infectious diseases, pain and inflammation, cardiovascular diseases and dermatological conditions. The company's strategy is to: 1) identify and acquire promising, early-stage research projects and developing technologies that address unmet medical needs and have large potential markets; 2) form eminent Scientific Advisory Boards to design "proof of principle" experiments to validate the technology; 3) immediately following successful completion of these experiments, commercialize or sublicense such technology by entering into agreements with one or more major pharmaceutical companies for full clinical development, manufacturing and marketing. Atlantic has developed a proprietary instrument system and associated single procedure disposable attachments -- Catarex(TM) -- for cataract removal. This device, if approved, may allow cataract removal in less than 10 minutes, through a lmm operative incision. Atlantic is developing enhancing technology for antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid). therapeutics. This is based on a proprietary, antisense-linked activator of an intracellular enzyme, RNaseL, which leads to rapid, selective destruction of mRNA targets. Two other promising technologies include CT-3 and sulfated cyclodextrins (CT-1 and CT-2). CT-3 is a novel molecule which, in early studies, has exhibited marked anti-inflammatory and analgesic analgesic (ăn'əljē`zĭk), any of a diverse group of drugs used to relieve pain. Analgesic drugs include the nonsteroidal anti-inflammatory drugs (NSAIDs) such as the salicylates, narcotic drugs such as morphine, and synthetic drugs effects without causing any gastric ulceration ulceration /ul·cer·a·tion/ (ul?ser-a´shun) 1. the formation or development of an ulcer. 2. an ulcer. ul·cer·a·tion n. 1. Development of an ulcer. 2. . CT-1 and CT-2 are able to avidly bind growth factors which are responsible for vascular restenosis (narrowing). This problem commonly occurs after angioplasty, bypass surgery Bypass surgery A surgical procedure that grafts blood vessels onto arteries to reroute the blood flow around blockages in the arteries (arteriosclerosis). and within arteriovenous shunts. Stock range: 12/14/95-3/19/96; $4.50-$10.50 ATLC ATLC Arbitrary Transmission Line Calculator ATLC Atomic Trades and Labor Council ATLC Air Transport Label Catalog ATLC Advanced Technology Licensing Company CONTACT: Atlantic Pharmaceuticals, Inc. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion